Gina Mauro


Maintenance Lenalidomide Safe, Should Be Continued in Patients With Myeloma Who Contract COVID-19

March 5th 2021

Maintenance treatment with lenalidomide was found to be a safe treatment for patients with multiple myeloma who are diagnosed with COVID-19, supporting use of the immunomodulatory drug in this patient population.

Melphalan Triplets Elicit Responses, Are Safe in Relapsed/Refractory Multiple Myeloma

March 5th 2021

The triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib demonstrated encouraging clinical activity and was well tolerated in patients with heavily pretreated relapsed/refractory multiple myeloma.

Ixazomib Triplets Show Efficacy in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

March 4th 2021

Ixazomib-based triplet regimens as induction therapy elicited higher rates of efficacy compared with ixazomib/dexamethasone alone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma.

Chemoimmunotherapy Remains Frontline Standard in Indolent Non-Hodgkin Lymphoma, But Novel Approaches Under Exploration

March 1st 2021

Chemoimmunotherapy has maintained its role as a go-to frontline approach in patients with indolent non-Hodgkin lymphoma.

Explosion of Data Come From Innovative Combos in CLL

February 26th 2021

The progress made with novel combination regimens coupled with their game-changing data in both frontline and relapsed/refractory chronic lymphocytic leukemia is unprecedented.

Dostarlimab Gets Positive EU Opinion in Recurrent or Advanced MSI-H Endometrial Cancer

February 26th 2021

February 26, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion to dostarlimab as a treatment for patients with recurrent or advanced microsatellite instability–high/mismatch repair deficient endometrial cancer who have progressed on or following platinum-based chemotherapy.

Reduced Vincristine/Dexamethasone Dosing Schedule Shows Impressive Outcomes, Improved QoL in Pediatric B-ALL

February 19th 2021

A reduced frequency of maintenance vincristine and dexamethasone led to a 5-year overall survival rate of 98.6% and improved quality of life in pediatric patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia.

Combos Lead Excitement in BRAF+ Melanoma, But More Pain Points Are Ready to Be Tackled

February 18th 2021

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

VHL Disease: Monitoring Is Imperative, But Research Efforts Are Gaining Ground

February 16th 2021

VHL disease is defined as a rare, inherited disorder that causes tumors and cysts to grow in specific areas of the body, including the brain, spinal cord, eyes, inner ear, adrenal glands, pancreas, kidney, and reproductive tract.

NBTXR3 Activity in Soft Tissue Sarcoma Could Be Replicated in Other Cancers

February 15th 2021

NBTXR3, a novel radioenhancer, is showing intriguing response rates in adult patient with soft tissue sarcoma, paving a path for the innovative therapy not just in sarcomas, but other tumor types, as well.